Loading...
In 2016, results from the manufacturer-funded KEYNOTE-024 study led to a paradigm shift in first-line management of a subset of patients with metastatic non–small-cell lung cancer (NSCLC) that expressed PD-L1 ≥50%. In that study, pembrolizumab monotherapy was associated with a significant and clinically meaningful improvement in overall survival and progression-free survival compared to chemotherapy. Now, researchers report 5-year outcomes.
In this trial, participants had PD-L1 tumor proportion scores of ≥50%, lacked an EGFR mutation or ALK translocation, and were randomized to pembrolizumab or standard histology-specific, platinum-based chemotherapy. At a median follow-up of 59.9 months, improvement in survival with pembrolizumab was signif…